Clinical Trials Logo

Clinical Trial Summary

To test the hypothesis that functionally navigated repetitive TMS stimulations to the prefrontal cortex (PFC) modulate aberrant cortical electrical activities at PFC circuitry. The TMS location of the PFC site will be individually localized by the symptom-related functional connectivity between PFC and symptom related areas (such as the auditory and language processing cortex). The investigators predict that such modulation will correct abnormal activities in patients with schizophrenia, reduce symptoms, especially auditory hallucination, and improve working memory/sustained attention performance.


Clinical Trial Description

Neuroimaging studies suggest that aberrant activities at specific brain regions such as sensory areas and language-related areas are related to psychosis symptoms including auditory and visual hallucination, delusion, and thought disorders. Transcranial magnetic stimulation (TMS) provides a non-invasive means for altering brain electrical neural activity. TMS has been approved by FDA for treatment of depression. Other applications have not been approved but it has been used in a wide range of clinical research especially in neurology and psychiatry. Among psychotic symptoms, there are preliminary significant improvement in treatments of auditory hallucination using TMS with small samples, but those treatments are not robust in larger samples. The high inter-subject variability limits the efficacy of TMS treatment in schizophrenia patients. The investigators aim to develop a TMS treatment method with a fMRI-defined treatment target area, where the TMS target is individually identified to maximize the TMS effects. The identification method uses both the anatomical character and its functional relationship with auditory hallucination and other psychosis symptoms. If the current target-identification successfully identified effective TMS target individually, the treatment efficacy will be significant improved and more patients will benefit from TMS treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02916810
Study type Interventional
Source University of Maryland, Baltimore
Contact Xiaoming Du, PhD
Phone 410-402-6036
Email xdu@mprc.umaryland.edu
Status Recruiting
Phase N/A
Start date October 2016
Completion date July 2025

See also
  Status Clinical Trial Phase
Completed NCT05083377 - Clozapine Use Pattern in the Province of Seville
Recruiting NCT06313918 - Exercise Therapy in Mental Disorders-study N/A
Recruiting NCT06134661 - Accelerated rTMS for Psychomotor Slowing N/A
Completed NCT01433094 - Study on Psychoeducation Enhancing Results of Adherence in Schizophrenia N/A
Terminated NCT05526833 - An Extension Protocol for Patients Who Previously Completed the TMS Pilot Study N/A
Recruiting NCT05982158 - Avatar-mediated Therapy Versus Cognitive Behavioural Therapy for Persisting Experiences of Hearing Voices N/A
Active, not recruiting NCT06175559 - Embedded Narrative in Interactive Game Design for Improving Medication Adherence of Schizophrenia N/A
Active, not recruiting NCT05673941 - "InMotion" - Physical Training With Creative Movement as an Intervention for Adults With Schizophrenia N/A
Recruiting NCT05958875 - The Effect of a Six Week Intensified Pharmacological Treatment for Schizophrenia Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. Phase 4
Recruiting NCT03525054 - Semantic and Syntactic Computerized Analysis of Free Speech
Recruiting NCT05389345 - tDCS and Executive Function Training for Schizophrenia N/A
Completed NCT05601050 - Linguistic Predictors of Outcomes in Psychosis
Completed NCT03075202 - Role of an E-cigarette on Smoking Displacement in Smokers With Schizophrenia
Completed NCT03921450 - Overcoming Psychomotor Slowing in Psychosis (OCoPS-P) N/A
Completed NCT06231407 - Increasing Medication Check Participation Through Applying CT-r N/A
Recruiting NCT04478838 - "Extended" (Alternate Day) Antipsychotic Dosing Phase 4
Completed NCT04366401 - Efficacy of Prebiotic and Probiotic Dietary Modulation in Schizophrenic Disorders N/A
Completed NCT04612777 - A Trial of "Opening Doors to Recovery" for Persons With Serious Mental Illnesses N/A
Not yet recruiting NCT06191965 - MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction Phase 2/Phase 3
Recruiting NCT04321759 - Comparative Effectiveness of CET vs. SST in SMI (Serious Mental Illness) N/A